Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

Authors: Yu et al.

Lancet Neurol. 2023 Jun;22(6):476-484.

PMID: 37210098 | DOI: 10.1016/S1474-4422(23)00126-6

See related comment.

Sign Up For An MSC Newsletter

Become an MSC member!

Join the Migraine Science Collaborative by becoming a member! Membership gives you the opportunity to contribute to the site, and it helps build community and raise awareness of headache conditions. Visit here to sign up for free.



  • Content Types

  • Paper Categories

  • Paper Dates

Paper Categories

By Date